Vancouver, British Columbia – TheNewswire - January 8, 2025 – MindBio Therapeutics Corp. (CSE: MBIO); (Frankfurt: WF6), (the “Company” or “MindBio”), a biotechnology company that conducts clinical health research and has developed a world first AI prediction tool for drug and alcohol intoxication detection using the human voice, is pleased to announce that CEO, Justin Hanka will be presenting at the upcoming 9th Annual Neuroscience Innovation Forum in San Francisco.

The Company’s involvement in the Neuroscience Innovation Forum marks the beginning of a roadshow through Silicon Valley during the 44th annual JP Morgan Healthcare Conference week.  The Company’s executives will be meeting with a wide range of technology and healthcare investors to introduce the Company’s innovative voice activated and AI powered intoxication detection technologies that use the human voice to assess drug and alcohol intoxication.  In a world first, MindBio has developed an AI model that uses over 50 million data points to predict alcohol intoxication with remarkable accuracy, just by using the human voice.  The technology goes further to estimate actual blood alcohol concentration levels in the successful 2025 launch of the Booze AI app, app.booze-ai.com.

The Company is developing an enterprise version and new platform level technology for health prediction using the human voice and is expanding its drug and alcohol intoxication technology for use in workplace environments, call centres, mental health and law enforcement and the Company hopes to make announcements about the progress of the new technology, new products and markets and potential commercial applications, shortly.

  

For further information, please contact:

 

Justin Hanka, Chief Executive Officer

61 433140886

justin@mindbiotherapeutics.com

www.mindbiotherapeutics.com

 

About MindBio Therapeutics

MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6) is a clinical-stage biotechnology company headquartered in Vancouver, British Columbia, that for several years has been conducting clinical trials and is focused on developing novel treatments for mental health disorders and health prediction technologies using AI and machine learning.  The Company has expertise in developing speech analytics as a prediction tool for drug and alcohol intoxication.

Cautionary Note Concerning Forward-Looking Statements:

The press release contains "forward-looking statements" within the meaning of applicable securities laws. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "budget," "believe," "project," "estimate," "expect," "scheduled," "forecast," "strategy," "future," "likely," "may," "to be," "could," "would," "should," "will" and similar references to future periods or the negative or comparable terminology, as well as terms usually used in the future and conditional. Forward-looking statements are based on assumptions as of the date they are provided. However, there can be no assurance that such assumptions will reflect the actual outcome of such items or factors.

Additionally, there are known and unknown risk factors that could cause the Company's actual results and financial conditions to differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important risk factors that could cause actual results and financial conditions to differ materially from those indicated in the forward-looking statements, include among others: general economic, market and business conditions in Canada and Australia; market volatility; unforeseen delays in timelines for any of the transactions or events described in this press release.  All forward-looking information is qualified in its entirety by this cautionary statement.

The Company disclaims any obligation to revise or update any such forward-looking statement or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

Neither the Canadian Securities Exchange nor its Regulation Service Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.